Amphetamine-induced striatal dopamine release in schizotypal personality disorder

Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregi...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacology 2020-09, Vol.237 (9), p.2649-2659
Main Authors: Thompson, Judy L., Rosell, Daniel R., Slifstein, Mark, Xu, Xiaoyan, Rothstein, Ethan G., Modiano, Yosefa A., Kegeles, Lawrence S., Koenigsberg, Harold W., New, Antonia S., Hazlett, Erin A., McClure, Margaret M., Perez-Rodriguez, M. Mercedes, Siever, Larry J., Abi-Dargham, Anissa
Format: Article
Language:English
Subjects:
Adolescent
Adult
Amphetamine - pharmacology
Amphetamines
Biomedical and Life Sciences
Biomedicine
Brain research
Cognitive ability
Corpus Striatum - diagnostic imaging
Corpus Striatum - drug effects
Corpus Striatum - metabolism
Dopamine
Dopamine - metabolism
Dopamine D2 receptors
Dopamine Uptake Inhibitors - pharmacology
Female
Humans
Male
Medical colleges
Memory, Short-Term - drug effects
Memory, Short-Term - physiology
Mental disorders
Middle Aged
Neostriatum
Neurosciences
Original Investigation
Personality
Personality disorders
PET imaging
Pharmacology/Toxicology
Phenols
Positron emission tomography
Positron-Emission Tomography - methods
Psychiatry
Raclopride
Receptors, Dopamine D2 - metabolism
Schizophrenia
Schizotypal personality disorder
Schizotypal Personality Disorder - diagnostic imaging
Schizotypal Personality Disorder - metabolism
Schizotypal Personality Disorder - psychology
Short term memory
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods We used positron emission tomography with [ 11 C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP ND ), and its percent change post-amphetamine (∆BP ND ) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results There were no significant group differences in BP ND or ∆BP ND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP ND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP ND in several striatal subregions. Conclusions In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.
ISSN:0033-3158
1432-2072
DOI:10.1007/s00213-020-05561-5